NP276006.RASUL3ogIhS0 u79vrHzNFR8-PedzqdQAtE WnyjU-x-4
type: Nanopublication
has assertion: NP276006.RASUL3ogIhS0 u79vrHzNFR8-PedzqdQAtE WnyjU-x-4130 assertion
has provenance: NP276006.RASUL3ogIhS0 u79vrHzNFR8-PedzqdQAtE WnyjU-x-4130 provenance
has publication info: NP276006.RASUL3ogIhS0 u79vrHzNFR8-PedzqdQAtE WnyjU-x-4130 publicationInfo
created: 2016-05-13T12:43:51+02:00
rights: http://opendatacommons.org/licenses/odbl/1.0/
rights holder: IBIGroup
subject: SIO_000983
used data: disgenetv3.0rdf
authored by: http://orcid.org/0000-0001-5999-6269
authored by: http://orcid.org/0000-0002-7534-7661
authored by: 0000-0002-9383-528X
authored by: http://orcid.org/0000-0003-0169-8159
authored by: http://orcid.org/0000-0003-1244-7654
created by: http://orcid.org/0000-0003-0169-8159
version: v4.0.0.0

NP276006.RASUL3ogIhS0 u79vrHzNFR8-PedzqdQAtE WnyjU-x-4130 assertion
type: Assertion
description: [To evaluate whether p21 (WAF-1/CIP1) should be considered a potential candidate for human bladder cancer gene therapy, we determined: (1) the basal level of p21 expression in bladder cancer cell lines, (2) the response of bladder cancer cells to increased p21 expression following p21 adenovirus infection, and (3) the mechanism of growth inhibition produced by p21 overexpression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine.
evidence: DisGeNET evidence - LITERATURE
SIO_000772: http://identifiers.org/pubmed/10688044
was generated by: ECO_0000203

befree-2016
imported on: 2016-02-19

DisGeNET evidence - LITERATURE
type: ECO_0000212
comment: Gene-disease associations inferred from text-mining the literature.

disgenetv3.0rdf
version: v4.0.0